MedTrace Logo

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

NCT02844777 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2023-01-12

Study results available
· View outcomes & findings →

Summary

This Phase 2 clinical trial is a multi-center, randomized, double-blind, placebo-controlled, multiple-dose, parallel-cohort study to assess the efficacy, safety and tolerability of VDA-1102 in the treatment of actinic keratosis (AK) on the head of male and female adult subjects.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Placebo

200 mg applied once-daily for 28 days

DRUG

5% VDA-1102

200 mg applied once-daily for 28 days

DRUG

10% VDA-1102

200 mg applied once-daily for 28 days

Sponsors & Collaborators

  • Vidac Pharma

    lead INDUSTRY

Principal Investigators

  • Chaim M Brickman, MD · Vidac Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-15
Primary Completion
2017-05-26
Completion
2017-05-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02844777 on ClinicalTrials.gov